逸達生物科技 Foresee Pharmaceuticals Co., Ltd.
About Us
Company Profile
Business Model
Board of Directors
Management Team
Company Partners
Scientific Advisory Board
Others
R & D
Pipeline Overview
SIF Pipeline
FP-001：Prostate Cancer
FP-004：Opioid Dependence/Pain
FP-011：Breast Cancer/Prostate Cancer
FP-014：Breast Cancer/Prostate Cancer
FP-015：Neurology
Other Research Projects
NCE Pipeline
FP-045: Fanconi Anemia
FP-025：Asthma and COPD; ARDS in COVID-19 Patients
FP-040: CNS Diseases
FP-020: Alport Syndrome
Media
Press Release
Media Library
Investors
Corporate Governance
Corporate Structure
Board of Directors
Corporate Charters
Others
Material Information
News & Events
Press Releases
Events & Presentations
Financial Information
Financial Results
Monthly Revenues
Sharholder Information
Annual General Meeting
Major Shareholders
FAQs
Investor Contacts
Others
Career
WELFARE & BENEFITS
Join Us
Contact Us
繁體中文
HOME
繁體中文
HOME
Latest News
Foresee Pharmaceuticals Announces NDA for CAMCEVI™ 42MG Accepted for Review by the FDA
Foresee Pharmaceuticals to Present in 2020 Fanconi Anemia Scientific Symposium
Foresee Pharmaceuticals and Accord Healthcare Announce MAA Submission for CAMCEVI™ 42MG
Press Release
Pipeline Overview
Financial Information
Company Partners
